CATX Perspective Therapeutics
- 4.3500
- +0.2300+5.58%
- 4.3201
- -0.0299-0.69%
Perspective Therapeutics News
Perspective Therapeutics Is Maintained at Outperform by RBC Capital
BofA Securities Maintains Perspective Therapeutics(CATX.US) With Hold Rating, Maintains Target Price $6
RBC Capital Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Cuts Target Price to $16
RBC Cuts Price Target on Perspective Therapeutics to $16 From $25, Keeps Outperform, Speculative Risk
Cautious Hold Rating for Perspective Therapeutics Amid Efficacy and Safety Concerns
Perspective Therapeutics Is Maintained at Outperform by Oppenheimer
Perspective Therapeutics Analyst Ratings
Oppenheimer Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Cuts Target Price to $16
Truist Financial Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Maintains Target Price $21
Truist Financial Releases a Buy Rating on Perspective Therapeutics (CATX)
JonesTrading Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Maintains Target Price $21
Cautious Optimism: Justin Walsh's Buy Rating on Perspective Therapeutics Amidst Mixed Trial Results
LifeSci Capital Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Maintains Target Price $21
RBC Capital Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Maintains Target Price $25
Truist Financial Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Maintains Target Price $21
JonesTrading Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Maintains Target Price $21
Oppenheimer Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Maintains Target Price $22
LifeSci Capital Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Maintains Target Price $21
Buy Rating for Perspective Therapeutics Due to Clinical Progress and Strategic Manufacturing Expansion
Truist Financial Maintains Perspective Therapeutics(CATX.US) With Buy Rating
Analysis
Price Target
No Data
No Data